---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-120772"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:46:20.677571+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed

## Summary
- Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.
- Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.
- FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.
- R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.
- Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025.

## SEC filing metadata
- accession: 0001193125-25-120772
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/0001193125-25-120772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/d818687d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-120772
- JSON: https://secwatch.observer/filing/0001193125-25-120772.json
- Plain text: https://secwatch.observer/filing/0001193125-25-120772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.